DDInter1821 DDInter1376
Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Tizanidine {u} (Compound) resembles {v} (Compound) Brimonidine
Tizanidine {u} (Compound) binds {v} (Gene) CYP1A2
Tizanidine {u} (Compound) upregulates {v} (Gene) CDK6
Tizanidine {u} (Compound) palliates {v} (Disease) multiple sclerosis
Tizanidine {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic alpha2-Agonists
Tizanidine {u} (Compound) downregulates {v} (Gene) USP22
Tizanidine {u} (Compound) causes {v} (Side Effect) Autonomic nervous system imbalance
Tizanidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Tizanidine (Compound) resembles Brimonidine (Compound)
Tizanidine (Compound) binds CYP1A2 (Gene)
Tizanidine (Compound) upregulates CDK6 (Gene)
Tizanidine (Compound) palliates multiple sclerosis (Disease)
Tizanidine (Compound) is included by Adrenergic alpha2-Agonists (Pharmacologic Class)
Tizanidine (Compound) downregulates USP22 (Gene)
Tizanidine (Compound) causes Autonomic nervous system imbalance (Side Effect)
Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a